A comparison of three free and total PSA assays

Prostate Cancer and Prostatic Diseases

Volumn 1, Issue 6, 1998, Pages 326-331

  Roth, H J ^a   Stewart, S C ^b   Brawer, M K ^c  

^a Laboratory Group Heidelberg   (United States)

^b Clinical Studies Specialist   (United States)

^c Northwest Prostate Institute   (United States)

Author keywords

Free; Isoforms; Prostate specific antigen; Total

Indexed keywords

EID: 0000519417     PISSN: 13657852     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.pcan.4500264     Document Type: Article

References (18)

1. Catalona WJ et al. Measurement of PSA in serum as a screening test for prostate cancer. NEJM 1991; 324: 1156-1161.
2. Brawer MK et al. Screening for prostatic carcinoma with PSA. J Urol 1992; 147: 841-845.
3. Cooner WH et al. Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate-specific antigen. J Urol 1990; 143: 1146-1152.
4. Babaian RJ, Camps JL The role of PSA as part of the diagnostic triad and as a guide when to perform a biopsy. Cancer 1991; 68: 2060-2063.
5. Nixon RG, Brawer MK Refinements in serum prostate-specific antigen testing for the diagnosis of prostate cancer, In: O'Leary MP, Kirby R (eds.) Recent advances in Urology. Churchill Livingstone: London, 1998.
6. Brawer MK, Kirby RS (eds.). Fast Facts: PSA Health Press: London, 1998.
7. Luderer AA et al. Measurement of the proportion of free to total PSA improves diagnostic performance of PSA in the diagnostic gray zone of total PSA. Urology 1995; 46: 187-194.
8. Catalona WJ et al. Evaluation of percentage of free serum PSA to improve specificity of prostate cancer screening. JAMA 1995; 274: 1214-1220.
9. Woodrum DL et al. Interpretation of free prostate-specific antigen clinical research studies for the detection of prostate cancer. J Urol 1998; 159: 5-12.
10. Bangma CH, Kranse R, Blijenberg BG, Schroder FH. The value of screening tests in the detection of prostate cancer. Part I: Results of a retrospective evaluation of 1726 men. Urology 1995; 46: 773-778.
11. Bangma CH, Kranse R, Blijenberg BG, Schroder FH. The value of screening tests in the detection of prostate cancer: Retrospective analysis of free/total prostate-specific antigen ratio, age-specific reference ranges, and PSA density. Urology 1995; 46: 779.
12. Chen Y et al. Using proportions of free to total prostate-specific antigen, age, and total prostate-specific antigen to predict the probability of prostate cancer. Urology 1996; 47: 518-524.
13. Prestigiacomo AF et al. A compariosn of the free fraction of serum prostate-specific antigen in men with benign and cancerous prostates: The best case scenario. J Urol 1996; 156: 350-354.
14. Elgamal A et al. Free-to-total prostate-specific antigen ratio as a single test for detection of significant stage Tic prostate cancer. J Urol 1996; 156: 1042-1049.
15. Van Cangh PJ et al. Free to total prostate-specific antigen (PSA) ratio is superior to total-PSA in differentiating benign prostate hypertrophy from prostate cancer. Prostate Suppl 1996; 7: 30.
16. Partin AW et al. Analysis of percent free PSA for prostate cancer detection: Influence of total PSA, prostate volume and age. Urology 1996; 48: 55-61.
17. Nixon RG, Gold MH, Blase AB, Meyer GE, Brawer MK. Comparison of three investigative assays for the free form of prostate-specific antigen. J Urol 1998; 160: 420-425.
18. Christensson AG, Abrahamsson PA, Bjork T, Cockett AT, Lilja H. An increased proportion of the serum PSA complexed to alpha-1 antichymotrypsin discriminates prostate cancer from benign prostatic hypertrophy. J Urol 1992; 147: 706.